EPREX*1SIR 40000UI/ML 1ML ( DrugBank: - )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 2 |
| 18 | 脊髄小脳変性症（多系統萎縮症を除く。） | 1 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-001329-26-IT (EUCTR) | 03/08/2011 | 17/11/2011 | Erythropoietin in Amyotrophic Lateral Sclerosis: a study to identify the best dose and the optimal route of administration and evaluate the safety | ErythroPOietin in ALS: a Study of dose-finding and Safety - EPOSS2010 | Amyotrophic Lateral Sclerosis MedDRA version: 14.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: EPREX*1SIR 40000UI/ML 1ML INN or Proposed INN: ERYTHROPOIETIN | ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Italy | |||
| 2 | EUCTR2009-016066-91-IT (EUCTR) | 10/03/2010 | 17/11/2009 | SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL - ND | SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL - ND | ALS MedDRA version: 9.1;Level: SOC;Classification code 10029205 | Trade Name: EPREX*1SIR 40000UI/ML 1ML INN or Proposed INN: Erythropoietin | ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy |
18. 脊髄小脳変性症（多系統萎縮症を除く。）
臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-006156-37-IT (EUCTR) | 10/07/2012 | 26/07/2012 | Erythropoieitn in Friedreich Ataxia | A double-blind, randomized, placebo-controlled, clinical trial to test the efficacy of Epoetin alfa on physical performance of Friedreich Ataxia patients. - FRIEMAX | FRIEDREICH ATAXIA MedDRA version: 14.1;Level: PT;Classification code 10008025;Term: Cerebellar ataxia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: EPREX*1SIR 40000UI/ML 1ML INN or Proposed INN: EPOETIN ALFA Trade Name: EPREX*1SIR 10000UI 1ML INN or Proposed INN: EPOETIN ALFA Trade Name: BINOCRIT*1SIR 40000UI/1ML INN or Proposed INN: EPOETIN ALFA | UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | Italy |